Targeted delivery of doxorubicin through conjugation with <scp>EGF</scp> receptor–binding peptide overcomes drug resistance in human colon cancer cells

Abstract

DOX-EBP can overcome DOX resistance of tumour cells and increase in vivo antitumour efficacy. Therefore, it has the potential to be a potent therapeutic agent for treating drug-resistant cancers.